CME Information: Crohn’s Disease

MEETING THE CHALLENGE OF MANAGING CROHN’S DISEASE ACROSS THE SPECTRUM

Presented by the Albert Einstein College of Medicine and Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC

 

ACKNOWLEDGEMENT
This activity is supported an educational grant from Takeda Pharmaceuticals USA, Inc. and UCB, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2.0 hour of Category 1 credit for completing this program

DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, November 29, 2016 from 3:00 PM EST – 4:00 PM EST
Enduring Material
The enduring material will be available from November 29, 2016 to May 29, 2017

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Outline the recommended treatment algorithm for mild-to-moderate active disease
Describe the efficacy and risks associated with available therapies for moderate–to–severe active disease
Identify new treatments on the horizon and their potential place in therapy

 

TARGET AUDIENCE
Gastroenterologists, primary care and family medicine physicians, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers caring for patients with Crohn’s disease.

ESTIMATED TIME TO COMPLETE
This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters Disclosures
Joshua R. Korzenik, MD

Consulting fee: AbbVie; Genentech; Roche
Royalty: ColonaryConcepts
Contracted Research: AbbVie; Janssen

 

Peer Reviewer Disclosures
Lawrence J. Brandt, MD, MD

Has no disclosures to report relevant to this activity.

 

Providers Disclosures
Einstein–Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
 

PlatformQ Health Education, LLC Reported Financial Relationship
Hamsa Jaganathan, PhD, Medical Director
Has nothing to disclose.
Karen Greb–Murphy, Program Manager
Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org

For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at Support@ImmunologyLive.com.

DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, ImmunologyLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.